カテゴリ： GlobalData, イギリス, 企業調査

Summit Therapeutics Plc (SUMM)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Summit Therapeutics Plc (SUMM) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C3501
◆発行会社（調査会社）：GlobalData
◆発行日：2018年8月
◆ページ数：72
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：イギリス
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Summit Therapeutics Plc (Summit), formerly Summit Corp Plc is a clinical-stage drug discovery and development company that offer therapies. The company conducts research and development on the treatment of rare diseases and infectious diseases including duchenne muscular dystrophy and the infectious disease caused by the bacteria C difficile. It develops ridinilazole, an antibiotic that has the potential to treat CDI and reduce disease recurrence. Summit undertakes utrophin modulation program for duchenne muscular dystrophy. The company also develops novel antibiotic program for the treatment of superbug C. difficile. It operates through other pharmaceutical companies and charity foundations and parent advocacy groups. The company operates through its office located in Cambridge, the US. Summit is headquartered in Abingdon, the UK.

Summit Therapeutics Plc (SUMM) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Summit Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Summit Therapeutics Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Summit Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Summit Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Summit Therapeutics Plc, Medical Devices Deals, 2012 to YTD 2018 10
Summit Therapeutics Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Summit Therapeutics Plc, Pharmaceuticals & Healthcare, Deal Details 13
Partnerships 13
Summit (Oxford) Enters into Contract with Biomedical Advanced Research and Development Authority 13
Summit Therapeutics Enters into Agreement with University of Oxford 14
Licensing Agreements 15
Summit Therapeutics Enters into Licensing Agreement with Eurofarma Laboratorios 15
Sarepta Therapeutics Enters into Licensing Agreement with Summit Therapeutics 16
Roche Expands its Licensing Agreement with Discuva 17
Summit Enters Into Licensing Agreement With Bristol-Myers Squibb For Seglin Technology 18
Equity Offering 19
Summit Therapeutics Plans to Raise up to USD225 Million in Public offering of Securities 19
Summit Therapeutics Raises USD21.3 Million in Private Placement of Shares 20
Summit Therapeutics Raises USD20.1 Million in Public Offering of Shares 22
Summit Therapeutics Raises Funds in Private Placement of Shares upon Exercise of Warrants 23
Summit Therapeutics Raises USD0.1 Million in Private Placement of Shares upon Exercise of Warrants 24
Summit Therapeutics Completes Initial Public Offering of American Depositary Shares 25
Summit Therapeutics Raises USD36.6 Million in Private Placement of Shares 27
Summit Completes Private Placement Of Shares For US$34.4 Million 28
Summit Completes Private Placement Of Shares For US$1.6 Million 29
Summit Completes Private Placement Of Shares For US$7 Million 30
Summit Completes Private Placement Of Shares For US$0.1 Million 31
Summit Announces Private Placement Of Shares For US$8 Million 32
Acquisition 33
Summit Therapeutics Acquires Discuva for USD13.3 Million 33
Summit Acquires MuOx for USD5.3 Million 34
Summit Therapeutics Plc – Key Competitors 35
Summit Therapeutics Plc – Key Employees 36
Summit Therapeutics Plc – Locations And Subsidiaries 37
Head Office 37
Other Locations & Subsidiaries 37
Recent Developments 39
Financial Announcements 39
Jun 05, 2018: Summit Therapeutics Reports Financial Results for the First Quarter Ended 30 April 2018 and Operational Progress 39
Apr 11, 2018: Summit Therapeutics Reports Financial Results for the Fiscal Year Ended 31 January 2018 40
Apr 11, 2018: Summit Therapeutics Reports Financial Results for the Fourth Quarter and Fiscal Year Ended 31 January 2018 and Operational Progress 47
Dec 06, 2017: Summit Therapeutics Reports Financial Results for the Third Quarter and Nine Months Ended 31 October 2017 and Operational Progress 48
Aug 31, 2017: Summit Therapeutics Reports Financial Results For The Second Quarter And Half Year Ended 31 July 2017 And Operational Progress 50
Jun 14, 2017: Summit Therapeutics Reports Financial Results For The First Quarter Ended 30 April 2017 And Operational Progress 53
Mar 29, 2017: Summit Therapeutics Reports 4th Quarter and Year End Financial Results and Operational Progress 55
Corporate Communications 56
May 23, 2017: Summit Announces Key Appointments to Strengthen Research & Development Team 56
Jan 18, 2017: Summit Appoints Dr David Roblin as Chief Operating Officer and President of Research & Development 58
Government and Public Interest 59
Jul 10, 2018: Summit Therapeutics Wins up to $4.5 Million Grant from CARB-X for Development of New Mechanism Gonorrhoea Antibiotics 59
Product News 60
04/23/2018: Summit Highlights Discovery of a Series of New Mechanism Antibiotics for the Treatment of Gonorrhoea in Late-Breaking Presentation at ECCMID 2018 60
Mar 13, 2018: Summit’s Infectious Diseases Technology Platform Yields Novel Antibiotics with Potential in Global Fight Against Gonorrhoea 61
Clinical Trials 62
Nov 20, 2017: Summit Completes Initial 24 Weeks Of Dosing Of Ezutromid In Patients With DMD In Phaseout DMD Clinical Trial 62
Oct 04, 2017: Summit Highlights DMD Biomarker Validation Data and Phase 2 Clinical Trial Baseline Characteristics in Presentations at 22nd WMS Congress 63
Sep 25, 2017: Summit Joins cTAP In Collaborative Effort To Enhance The Development Of Utrophin Modulators And Other Treatments For Duchenne Muscular Dystrophy 66
Jun 22, 2017: Summit Presents Data From Phase 1 Clinical Programme of Ezutromid at the European Paediatric Neurology Society Congress 67
May 15, 2017: Summit Completes Enrolment of PhaseOut DMD, a Phase 2 Clinical Trial of Ezutromid in Patients with DMD 68
Mar 27, 2017: Summit to Extend Ongoing PhaseOut DMD Clinical Trial of Ezutromid in Patients with DMD 69
Other Significant Developments 70
Mar 30, 2017: Summit Therapeutics: Change of Registered Office 70
Mar 30, 2017: Summit Announces Change Of Registered Company Address 71
Appendix 72
Methodology 72
About GlobalData 72
Contact Us 72
Disclaimer 72

List of Tables
Summit Therapeutics Plc, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Summit Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Summit Therapeutics Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Summit Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Summit Therapeutics Plc, Deals By Therapy Area, 2012 to YTD 2018 9
Summit Therapeutics Plc, Medical Devices Deals, 2012 to YTD 2018 10
Summit Therapeutics Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Summit (Oxford) Enters into Contract with Biomedical Advanced Research and Development Authority 13
Summit Therapeutics Enters into Agreement with University of Oxford 14
Summit Therapeutics Enters into Licensing Agreement with Eurofarma Laboratorios 15
Sarepta Therapeutics Enters into Licensing Agreement with Summit Therapeutics 16
Roche Expands its Licensing Agreement with Discuva 17
Summit Enters Into Licensing Agreement With Bristol-Myers Squibb For Seglin Technology 18
Summit Therapeutics Plans to Raise up to USD225 Million in Public offering of Securities 19
Summit Therapeutics Raises USD21.3 Million in Private Placement of Shares 20
Summit Therapeutics Raises USD20.1 Million in Public Offering of Shares 22
Summit Therapeutics Raises Funds in Private Placement of Shares upon Exercise of Warrants 23
Summit Therapeutics Raises USD0.1 Million in Private Placement of Shares upon Exercise of Warrants 24
Summit Therapeutics Completes Initial Public Offering of American Depositary Shares 25
Summit Therapeutics Raises USD36.6 Million in Private Placement of Shares 27
Summit Completes Private Placement Of Shares For US$34.4 Million 28
Summit Completes Private Placement Of Shares For US$1.6 Million 29
Summit Completes Private Placement Of Shares For US$7 Million 30
Summit Completes Private Placement Of Shares For US$0.1 Million 31
Summit Announces Private Placement Of Shares For US$8 Million 32
Summit Therapeutics Acquires Discuva for USD13.3 Million 33
Summit Acquires MuOx for USD5.3 Million 34
Summit Therapeutics Plc, Key Competitors 35
Summit Therapeutics Plc, Key Employees 36
Summit Therapeutics Plc, Other Locations 37
Summit Therapeutics Plc, Subsidiaries 37

List of Figures
Summit Therapeutics Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Summit Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Summit Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Summit Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Summit Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Summit Therapeutics Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Summit Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Summit Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Summit Therapeutics Plc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Summit Therapeutics Plc (SUMM)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • AFFiRiS AG-製薬・医療分野：企業M&A・提携分析
    Summary Affiris AG (AFFiRiS) is a drug development company that develops and manufactures novel synthetic vaccines against chronic diseases. The company develops customized peptide vaccines based on its proprietary affitome technology for the prevention of Alzheimer's disease, Parkinson's disease, a …
  • Arise AB (ARISE)：企業の財務・戦略的SWOT分析
    Arise AB (ARISE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Maxim Power Corp. (MXG)：電力：M&Aディール及び事業提携情報
    Summary Maxim Power Corp. (Maxim) is an independent power producing corporation that acquires, develops, owns and operates power generation facilities and sells electricity and heat. The corporation generates electricity using various fuel sources including coal, natural gas, and wind, nuclear, hydr …
  • Shanghai SECCO Petrochemical Co Ltd：企業の戦略的SWOT分析
    Shanghai SECCO Petrochemical Co Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • Samsung SDI Co Ltd (006400)：電力：M&Aディール及び事業提携情報
    Summary Samsung SDI Co., Ltd. (Samsung SDI) is a global manufacturer and distributor of the batteries. The company along with its subsidiaries carries out research and development, manufacturing, and marketing of a wide range of digital products such as small size Li-ion battery, automotive battery, …
  • Nichirei Corporation：企業の戦略・SWOT・財務分析
    Nichirei Corporation - Strategy, SWOT and Corporate Finance Report Summary Nichirei Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Sejal Glass Limited (SEZAL)：企業の財務・戦略的SWOT分析
    Sejal Glass Limited (SEZAL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Koninklijke Ten Cate NV：企業の戦略的SWOT分析
    Koninklijke Ten Cate NV - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • IVERIC bio Inc (ISEE)：企業の財務・戦略的SWOT分析
    Summary IVERIC bio Inc (IVERIC bio) formerly known as Ophthotech Corp, is a biopharmaceutical company that develops novel therapeutics to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases. The company’s products include Zimura, a complement inhibitor for stargardt di …
  • King Country Energy Limited：企業の戦略的SWOT分析
    King Country Energy Limited - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major product …
  • Gibson Energy Inc (GEI)：企業の財務・戦略的SWOT分析
    Gibson Energy Inc (GEI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • HNZ Group Inc.：戦略・SWOT・企業財務分析
    HNZ Group Inc. - Strategy, SWOT and Corporate Finance Report Summary HNZ Group Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • 23andMe Inc：医療機器：M&Aディール及び事業提携情報
    Summary 23andMe Inc (23andMe) is a biotechnology research and information provider that offers tools for health and ancestry care. The company offers raw genetic data and ancestry-related genetic reports. Its service portfolio includes clinical development, research and development, ancestry service …
  • Addison Lee Group：企業の戦略的SWOT分析
    Addison Lee Group - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Tokuyama Corp (4043)：企業の財務・戦略的SWOT分析
    Tokuyama Corp (4043) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Baoding Lightway Green Energy Technology Co Ltd：企業の戦略的SWOT分析
    Baoding Lightway Green Energy Technology Co Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competito …
  • Titan Medical Inc (TMD)-医療機器分野：企業M&A・提携分析
    Summary Titan Medical Inc (Titan) is a development stage company that designs and develops a robotic surgical system for application in minimally invasive surgery (MIS). The company's lead product candidate, single port robotic (SPORT) surgical system is a single-incision robotic surgical system tha …
  • Tenaska Energy, Inc.：企業の戦略・SWOT・財務情報
    Tenaska Energy, Inc. - Strategy, SWOT and Corporate Finance Report Summary Tenaska Energy, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Goldman Sachs Private Wealth Management：企業の戦略・SWOT・財務情報
    Goldman Sachs Private Wealth Management - Strategy, SWOT and Corporate Finance Report Summary Goldman Sachs Private Wealth Management - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT a …
  • Foxconn Technology Co Ltd：企業のM&A・事業提携・投資動向
    Foxconn Technology Co Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Foxconn Technology Co Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisi …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆